Single domain antibodies (sdAbs), derived from camelid antibodies, offer unique advantages such as smaller size, higher stability, and better tissue penetration compared to conventional antibodies. Alfa Cytology provides preclinical solutions for discovery and optimization of sdAbs, addressing the critical need for effective pancreatic cancer therapies. Our service includes comprehensive support from antigen identification and antibody generation to functional assays and preclinical validation.
Single Domain Antibody for Pancreatic Cancer Therapy
Therapeutic single domain antibodies, also known as VHHs or single-domain antibodies(sdAbs), are a novel class of antibodies derived from heavy-chain-only antibodies found in camelids. These antibodies are exceptionally small, typically around 12-15 kDa, which allows for superior tissue penetration and targeting of tumor microenvironments that are often inaccessible to conventional antibodies.
Fig. 1 General sdAb structure and types of sdAbs. (Sun Y, et al, 2023)
Single domain antibodies can be easily engineered and humanized, facilitating their translation from preclinical studies to potential clinical applications. In pancreatic cancer research, these antibodies play a crucial role in the identification and validation of novel therapeutic targets, the development of targeted therapies, and the enhancement of diagnostic accuracy.
Advantages of Therapeutic Single Domain Antibody
- Deep Tumor Penetration: Nanoscale dimensions for effective tumor and the blood-brain barrier (BBB) penetration.
- High Affinity and Specificity: High target affinity with minimal off-target effects.
- Robustness and Refolding Capacity: High resilience and refolding ability after denaturation.
- Thermal and Environmental Tolerance: Stability under extreme temperatures, pressures, and pH levels.
- Cost-effective Production: Inexpensive and straightforward microbial synthesis.
Our Services
Alfa Cytology's one-stop therapeutic antibody development service encompasses a wide array of integrated solutions designed to streamline the process from initial concept to preclinical validation. The scope includes bespoke antibody generation, affinity maturation, stability optimization, and comprehensive in vitro and in vivo validation. This holistic approach accelerates the development timeline and enhances the potential for successful therapeutic outcomes.
Targeted Receptors Selection
The therapeutic single domain antibody development service at Alfa Cytology targets a variety of receptors known to play critical roles in pancreatic cancer progression. These include:
Types of Therapeutic Single Domain Antibody
Alfa Cytology offers a variety of specialized therapeutic single domain antibody development services tailored to address different aspects of pancreatic cancer treatment.
Target-Specific sdAb
Focuses on creating sdAbs that bind specifically to unique pancreatic cancer markers, ensuring high specificity and reduced off-target effects.
Multi-Target sdAb
Involves the development of sdAbs that can simultaneously target multiple cancer-related antigens, providing a broader therapeutic impact.
Immune Checkpoint Inhibition sdAbs
Designed to block immune checkpoint proteins, these sdAbs help enhance the body's immune response against pancreatic cancer cells.
Intracellular Target sdAb
Targets intracellular signaling pathways crucial for cancer cell survival and proliferation, utilizing sdAbs' ability to penetrate cells more effectively than traditional antibodies.
Theranostic sdAb
Combines therapeutic and diagnostic capabilities, enabling both the treatment and real-time monitoring of pancreatic cancer progression.
Workflow of Single Domain Antibody Development
The process of developing therapeutic single domain antibodies for pancreatic cancer is structured into several key steps:
Antigen Identification
Identify and validate suitable antigens specific to pancreatic cancer cells using advanced bioinformatics and proteomics tools.
Antibody Library Construction
Generate a diverse library of single domain antibodies through phage display or other recombinant technologies.
High-Throughput Screening
Screen the antibody library against the identified antigens to select high-affinity binders using techniques such as ELISA and flow cytometry.
Functional Characterization
Assess the biological activity of selected sdAbs through in vitro assays, including cell proliferation, apoptosis, and signaling pathway analysis.
Preclinical Validation
Conduct in vivo studies in relevant animal models to evaluate the therapeutic potential and safety profile of the sdAbs.
Leveraging cutting-edge scientific research and advanced technological platforms, Alfa Cytology aims to create highly specific and potent therapeutic antibodies to combat pancreatic cancer. By offering comprehensive and specialized services, we help researchers and biotech companies accelerate the process of developing next-generation cancer therapies. Please contact us for more information.
Reference
- Yang E Y and Shah K. Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. Front. Oncol. 2020, 10:1182.
